<code id='4222AB0A68'></code><style id='4222AB0A68'></style>
    • <acronym id='4222AB0A68'></acronym>
      <center id='4222AB0A68'><center id='4222AB0A68'><tfoot id='4222AB0A68'></tfoot></center><abbr id='4222AB0A68'><dir id='4222AB0A68'><tfoot id='4222AB0A68'></tfoot><noframes id='4222AB0A68'>

    • <optgroup id='4222AB0A68'><strike id='4222AB0A68'><sup id='4222AB0A68'></sup></strike><code id='4222AB0A68'></code></optgroup>
        1. <b id='4222AB0A68'><label id='4222AB0A68'><select id='4222AB0A68'><dt id='4222AB0A68'><span id='4222AB0A68'></span></dt></select></label></b><u id='4222AB0A68'></u>
          <i id='4222AB0A68'><strike id='4222AB0A68'><tt id='4222AB0A68'><pre id='4222AB0A68'></pre></tt></strike></i>

          focus

          focus

          author:knowledge    Page View:97744
          From left: Daphne Koller, CEO of Insitro, Vijay Pande of Andreessen Horowitz and scientist Derek Lowe speaking at STAT's Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

          Artificial intelligence is a rapidly improving technology. But its progress in drug development faces an increasingly urgent threat: An unending stream of overheated marketing.

          To read of AI’s feats in press releases is to learn of a miracle product on the verge of unraveling biology’s most enduring secrets. It can map molecules and accurately predict how they fit together on computer screens. All you need to get to a cure — as they say in infomercials — is act now!

          advertisement

          “I am very worried about the hype,” said Daphne Koller, chief executive of the machine learning drug discovery company Insitro, said during STAT’s Breakthrough West Summit in San Francisco last week. “People think (the breakthrough) is going to happen tomorrow.”

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          CDC launches VaccineFinder tool to locate Covid
          CDC launches VaccineFinder tool to locate Covid

          AsignshowingpatientswheretoreceivetheirCovid-19vaccineinLouisville,Kentucky.Cherry/GettyImagesOnWedn

          read more
          Continuity nursing helped my family in our darkest PICU moments
          Continuity nursing helped my family in our darkest PICU moments

          EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3

          read more

          SCOTUS questions limit to govt efforts to fight misinformation

          STEFANIREYNOLDS/AFPviaGettyImagesWASHINGTON— MostoftheSupremeCourt’sjusticesonMondayseemedtoquestion